Today, December 17, JoVE, the Journal of Visualized Experiments, has published a novel technique that could resolve a snag in stem cell research for application in regenerative medicinea strategy for reprograming cells in vivo to act like stem cells that forgoes the risk of causing tumors.
Dr. Kostas Kostarelos, principal investigator of the Nanomedicine Lab at the University of Manchester, said that he and his colleagues have discovered a safe approach to reprogramming somatic cells (which constitute most of the cells in the body) into induced pluripotent stem (iPS) cells. Research in this field has been embraced as an alternative to the controversial use of embryonic stem cells.
"We have induced somatic cells within the liver of adult mice to transiently behave as pluripotent stem cells," said Dr. Kostas Kostarelos, the lab's principal investigator, "This was done by transfer of four specific genes, previously described by the Nobel-prize winning Shinya Yamanaka, without the use of viruses but simply plasmid DNA [a small circular, double-stranded piece of DNA used for manipulating gene expression in a cell]."
The technique comes as an alternative to Dr. Shinya Yamanaka's reprograming methods, which won him the Nobel prize in 2012. Dr. Yamanaka's approach involved reprogramming somatic cells in vitro by introducing four genes through the use of a virus. While promising, the use of this method has been limited. As Dr. Kostarelos's article states, "One of the central dogmas of this emerging field is that in vivo implantation of [these stem] cells will lead to their uncontrolled differentiation and the formation of a tumor-like mass."
Dr. Kostarelos and his team have determined that their technique does not share the risk of uncontrolled stem cell growth into tumors as seen in in vitro, viral-based methods. "[This is the] only experimental technique to report the in vivo reprogramming of adult somatic cells to plurip
|Contact: Rachel Greene|
The Journal of Visualized Experiments